Companies › Neurocrine Switzerland
1 active drug program in 2 registered trials: 2 Phase 2; Genitourinary; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Crinecerfont Corticotropin releasing factor receptor 1 antagonist | CRHR1 | Phase 2 | Congenital Adrenal Hyperplasia | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07536269 | Crinecerfont | Phase 2 | Congenital Adrenal Hyperplasia | Genitourinary | Mar 2028 |
| NCT07187375 | Crinecerfont | Phase 2 | Congenital Adrenal Hyperplasia | Genitourinary | Sep 2029 |
Cash and short-term investments of $738m on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Kira Pharmacenticals (US) Veloxis Pharmaceuticals Juro Sciences Vifor Fresenius Medical Care Renal Pharma Vaneltix Pharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.